RE: World-first veterinary anti-cancer drug launched

Arlo Guthrie — Sat, 13 Jun 2009 12:40:33 GMT

Yes, it could well be, but I am in touch with AB Science to see whether they would be interested in publishing the full study on VetSurgeon, so hold fire! Should know more next week.

RE: World-first veterinary anti-cancer drug launched

The SkepVet — Sat, 13 Jun 2009 12:36:20 GMT

Would this abstract be a good one to use with the new attempt on the list to use wikipedia to review abstracts?

art malernee dvm

RE: World-first veterinary anti-cancer drug launched

Alex Gough — Fri, 12 Jun 2009 14:55:43 GMT

Hopefully this will be a useful drug. It will be interesting to see if a consensus emerges amongst specialist oncologists as to when it is best to use it. There are so many options for mast cell tumours, with surgery and radiotherapy probably being gold standard, and surgery with chemotherapy being a good second best. In one study of 27 dogs with incompletely resected MCTs, treated with vinblastine and pred, only one dog experienced local recurrence, and 4 had developed distant cutaneous MCTs. In another study, median survival in high grade MCTs which were removed surgically had a median survival time of 1374 days.

Alex Gough

Bath Vet Referrals

RE: World-first veterinary anti-cancer drug launched

The SkepVet — Thu, 11 Jun 2009 15:18:14 GMT

Here is the abstract: it contains the most recent information I have about Palladia. Does anyone have any relative efficacy studies with a steriod to evaluate?

art malernee dvm

Clin Cancer Res. 2009 Jun 1;15(11):3856-65. Epub 2009 May 26.Click here to read Links

Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision.

London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM.

Authors' Affiliations: School of Veterinary Medicine, University of California, Davis, California.

PURPOSE: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell tumors (MCT) with toceranib phosphate (Palladia, SU11654), a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRbeta. Secondary objectives were to determine biological response rate, time to tumor progression, duration of objective response, health-related quality of life, and safety of Palladia. EXPERIMENTAL DESIGN: Dogs were randomized to receive oral Palladia 3.25 mg/kg or placebo every other day for 6 weeks in the blinded phase. Thereafter, eligible dogs received open-label Palladia. RESULTS: The blinded phase ORR in Palladia-treated dogs (n = 86) was 37.2% (7 complete response, 25 partial response) versus 7.9% (5 partial response) in placebo-treated dogs (n = 63; P = 0.0004). Of 58 dogs that received Palladia following placebo-escape, 41.4% (8 complete response, 16 partial response) experienced objective response. The ORR for all 145 dogs receiving Palladia was 42.8% (21 complete response, 41 partial response); among the 62 responders, the median duration of objective response and time to tumor progression was 12.0 weeks and 18.1 weeks, respectively. Palladia-treated responders scored higher on health-related quality of life versus Palladia-treated nonresponders (P = 0.030). There was no significant difference in the number of dogs with grade 3/4 (of 4) adverse events; adverse events were generally manageable with dose modification and/or supportive care. CONCLUSIONS: Palladia has biological activity against canine MCTs and can be administered on a continuous schedule without need for routine planned treatment breaks. This clinical trial further shows that spontaneous tumors in dogs are good models to evaluate therapeutic index of targeted therapeutics in a clinical setting.

Douglas H. Thamm, VMD, DACVIM (Oncology)

Assistant Professor, Oncology

Colorado State University Animal Cancer Center

dthamm@colostate.edu